Celltrion starts Phase I and Phase III clinical trials for Humira biosimilar

Published: 2018-08-09 16:28:00
Updated: 2018-08-09 16:41:31

Celltrion recently announced that they made a clinical trial application for ‘CT-P17,’ a biosimilar referencing the rheumatoid arthritis therapy ‘Humira(generic name: adalimumab),’ to the U.K. Medicines and Healthcare Products Regulatory Agency(MHRA).

Celltrion said they would start a Phase I cl...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.